Androgen Deprivation Therapy News and Research

RSS

Financial interests ‘driving IMRT uptake for prostate cancer’

A study suggests that the recent rapid uptake of intensity-modulated radiotherapy for prostate cancer in the USA has been driven by urologists with financial conflicts of interest.

5 Nov 2013

$IOF outlines guidelines to help prevent osteoporosis and fractures in cancer patients$

IOF outlines guidelines to help prevent osteoporosis and fractures in cancer patients

Cancer is a health burden of increasing importance which affects close to 13 million people globally. Bone is often affected in these patients, frequently because of bone metastases, or as a result of anti-cancer therapies which can contribute to bone loss and fragility.

4 Nov 2013

Qigong may help survivors of prostate cancer to combat fatigue

The flowing movements and meditative exercises of the mind-body activity Qigong may help survivors of prostate cancer to combat fatigue.

30 Oct 2013

Researchers identify existence of precursor cells in early prostate cancers

A team of cancer researchers at the University of California, San Diego has identified the existence of precursor cells in early prostate cancers. These cells are resistant to androgen-deprivation therapy, and may drive the subsequent emergence of recurrent or metastatic prostate cancer.

26 Sep 2013

Researchers identify key mechanism behind aggressive prostate cancer

A team of researchers from UC Davis, UC San Diego and other institutions has identified a key mechanism behind aggressive prostate cancer. Published on August 14 in Nature, the study shows that two long non-coding RNAs (PRNCR1 and PCGEM1) activate androgen receptors, circumventing androgen-deprivation therapy.

16 Aug 2013

ADT increases risk of kidney injury in patients with prostate cancer

In a study that included more than 10,000 men with nonmetastatic prostate cancer, use of androgen deprivation therapy (ADT) was associated with a significantly increased risk of acute kidney injury, with variations observed with certain types of ADTs, according to a study in the July 17 issue of JAMA.

17 Jul 2013

Abiraterone can prolong overall survival and delay severe pain in prostate cancer patients

Abiraterone acetate (abiraterone for short, trade name: Zytiga) has been approved in Germany since December 2012 for men with metastatic prostate cancer that is not responsive to hormone blockade, who only have mild symptoms or so far none at all, and in whom chemotherapy is not yet indicated.

3 Jul 2013

Prostate cancer patients need to be aware of the effects of androgen deprivation therapy

Androgen deprivation therapy is a common and effective treatment for advanced prostate cancer. However, among other side-effects, it can cause significant bone thinning in men on long-term treatment.

15 May 2013

Researchers find that VEGF may not have any prognostic value for advanced prostate cancer

The well-studied protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer, researchers from the Department of Radiation Oncology at Thomas Jefferson University Hospital and other institutions found in a retrospective study published online April 25 in the journal BMC Radiation Oncology.

30 Apr 2013

New risk classification system proposed for prostate cancer

US researchers have put forward a risk stratification system for patients with intermediate-risk prostate cancer undergoing dose-escalated external-beam radiation therapy.

29 Apr 2013

New risk classification system proposed for prostate cancer

US researchers have put forward a risk stratification system for patients with intermediate-risk prostate cancer undergoing dose-escalated external-beam radiation therapy.

25 Apr 2013

Study: microRNA is designed to stop proliferation of prostate cancer cells

The most recent in a series of studies from a team at the UC Davis Comprehensive Cancer Center has shown that a single molecule is at the heart of one of the most basic survival tactics of prostate cancer cells.

10 Apr 2013

Researchers study effectiveness of intermittent therapy for prostate cancer treatment

Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds.

4 Apr 2013

Prostate tissue androgen content predicts ADT outcome

Determining the androgen content in prostate tissue could predict patients’ responses to androgen deprivation therapy and the risk for castration-resistant prostate cancer, show study findings.

6 Mar 2013

Androgen deprivation therapy interferes with diabetes control

Androgen deprivation therapy for prostate cancer hampers glycemic control in men with diabetes, report researchers.

5 Mar 2013

GCP could help lengthen life expectancy of certain prostate cancer patients

A natural, nontoxic product called genistein-combined polysaccharide, or GCP, which is commercially available in health stores, could help lengthen the life expectancy of certain prostate cancer patients, UC Davis researchers have found.

21 Feb 2013

$ADT increases risk of fracture incidence after treatment completion in men with prostate cancer$

ADT increases risk of fracture incidence after treatment completion in men with prostate cancer

In what is believed to be the first study to describe the impact on men with a 'high' risk of bone fracture who are receiving long-term androgen deprivation therapy (ADT) for prostate cancer, new research from The Cancer Institute of New Jersey shows this population to have a higher fracture incidence following treatment completion.

18 Jan 2013